8NE2.F · Caladrius Biosciences, Inc

-

Please sign in to comment on 8NE2.F

1 Comment

Admin

4 years ago

Caladrius Biosciences, Inc is currently in a long term downtrend where the price is trading 15.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Caladrius Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 9.6% to $-5M since the same quarter in the previous year.

Finally, its free cash flow fell by 32.1% to $-6M since the same quarter in the previous year.

Based on the above factors, Caladrius Biosciences, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	None

PE Ratio	None
Target Price	10
Market Cap	2M
Dividend Yield	0.0%
Beta	0.91

ABOUT

Caladrius Biosciences, Inc

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

8NE2.F · Caladrius Biosciences, Inc

-

Caladrius Biosciences, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Caladrius Biosciences, Inc using a moving average strategy